Transcription factors interact with RNA to regulate genes.

Autor:	Oksuz O; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Henninger JE; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Warneford-Thomson R; Epigenetics Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Cell and Developmental Biology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA., Zheng MM; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Erb H; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Vancura A; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Overholt KJ; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Hawken SW; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Program of Computational & Systems Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Banani SF; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Lauman R; Epigenetics Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Cell and Developmental Biology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA., Reich LN; Epigenetics Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Cell and Developmental Biology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA., Robertson AL; Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA., Hannett NM; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Lee TI; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Zon LI; Stem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA; Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA., Bonasio R; Epigenetics Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Cell and Developmental Biology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA., Young RA; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: young@wi.mit.edu.
Jazyk:	angličtina
Zdroj:	Molecular cell [Mol Cell] 2023 Jul 20; Vol. 83 (14), pp. 2449-2463.e13. Date of Electronic Publication: 2023 Jul 03.
DOI:	10.1016/j.molcel.2023.06.012
Abstrakt:	Transcription factors (TFs) orchestrate the gene expression programs that define each cell's identity. The canonical TF accomplishes this with two domains, one that binds specific DNA sequences and the other that binds protein coactivators or corepressors. We find that at least half of TFs also bind RNA, doing so through a previously unrecognized domain with sequence and functional features analogous to the arginine-rich motif of the HIV transcriptional activator Tat. RNA binding contributes to TF function by promoting the dynamic association between DNA, RNA, and TF on chromatin. TF-RNA interactions are a conserved feature important for vertebrate development and disrupted in disease. We propose that the ability to bind DNA, RNA, and protein is a general property of many TFs and is fundamental to their gene regulatory function. Competing Interests: Declaration of interests R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, Dewpoint Therapeutics, and Paratus Sciences. R.A.Y. is a member of Molecular Cell’s advisory board. O.O. and J.E.H. are consultants at Camp4 Therapeutics. L.I.Z. is a founder and stockholder of Fate Therapeutics, Camp4 Therapeutics, Amagma Therapeutics, Scholar Rock, and Branch Biosciences. L.I.Z. is a consultant for Celularity and Cellarity. The Whitehead Institute has filed a patent application related to this work. (Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu